DelveInsight’s, “COVID-19 Pipeline Insight 2024” report provides comprehensive insights about 400+ companies and 400+ pipeline drugs in the COVID-19 pipeline landscape. It covers the COVID-19 pipeline drug profiles, including clinical and nonclinical stage products. It also covers the COVID-19 therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the COVID-19 Pipeline Report

• DelveInsight’s COVID-19 pipeline report depicts a robust space with 400+ active players working to develop 400+ pipeline therapies for COVID-19 treatment.
• The leading COVID-19 Companies working in the market include Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., TC BioPharm, Syntax for Science, S.L., Shaperon, Renibus Therapeutics, Quercis Pharma, Pharmenterprises, Pharmamel S.L., Orpheris, OPKO Health, Oncotelic Inc., Notitia Biotechnologies Company, Jazz Pharmaceuticals, Ionis Pharmaceuticals, Inotrem, Grifols Therapeutics LLC, Globavir Biosciences, Genentech, Inc., FSD Pharma, Faron Pharmaceuticals, Evergreen Therapeutics, Enlivex Therapeutics, Eiger BioPharmaceuticals, Direct Biologics, Debiopharm, Clene Nanomedicine, Chiesi Farmaceutici S.p.A., Cadila Healthcare Limited, Biotest, BeiGene, Apeiron Biologics, AgelessRx, AbbVie/Apotex, Telios Pharmaceuticals, Rapa Therapeutics, Organicell Regenerative Medicine, Miltenyi Biomedicine, MedRegen LLC, Kiadis Pharma, Kamada, Cellularity Incorporated, Bio-Thera Solutions, 3M, Sironax, Pfizer, Oncovir, Ology Bioservices, Neutrolis, NeoImmune Tech, Natureceuticals Sdn Bhd, Medicine Invention, Grand Medical, Frontier Biotechnologies, Emergent Biosolutions, Codagenix, Cellenkos, AlloVir, Bausch Health Americas, AiCuris, AgenTus Therapeutics, 4D Pharma, and others.
• Promising COVID-19 Therapies in the various stages of development include MAD0004J08, Calcium Dobesilate, Mannitol, IMU-838, Oseltamivir, ILT101, HLX71, and others.
• April 2024:- CytoDyn Inc.- A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Leronlimab in Patients Experiencing Prolonged Coronavirus Disease 2019 (COVID-19) Symptoms [Long-Haulers]. The purpose of this study is to assess the safety and efficacy of leronlimab (PRO 140) administered as weekly subcutaneous injections in subjects experiencing prolonged symptoms (> 12 weeks) of COVID-19.
• April 2024:- Novavax- A Multi-Part, Phase 3, Randomized, Observer Blinded Study to Evaluate the Safety and Immunogenicity of Omicron Subvariant and Bivalent SARS-CoV-2 rS Vaccines in Adults Previously Vaccinated With Other COVID-19 Vaccines. This is a Multi-Part, Phase 3, randomized, observer-blinded study to evaluate the safety and immunogenicity of booster doses of Omicron subvariant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) recombinant (r) spike (S) protein nanoparticle vaccines (SARS-CoV-2 rS) adjuvanted with Matrix-M™ adjuvant (NVX-CoV2515 [BA.1] and NVX-CoV2540 [BA.5]) and bivalent (NVX-CoV2373 [prototype] + Omicron subvariant) SARS-CoV-2 rS vaccines (NVX-CoV2373 + NVX CoV2515 and NVX CoV2373 + NVX CoV2540) in previously vaccinated adults 18 years of age and older.
• April 2024:- Shionogi- A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of S-217622 in the Prevention of Symptomatic SARS-CoV-2 Infection in Household Contacts of an Individual With Symptomatic COVID-19. The purpose of this study is to measure the proportion of participants who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (positive reverse transcription polymerase chain reaction [RT-PCR] test) and have coronavirus disease 2019 (COVID-19) symptom(s) with S-217622 tablets compared with placebo tablets in participants who are household contacts of an individual with symptomatic COVID-19.
• April 2024:- AstraZeneca- General Drug Use-Result Study of Evusheld Intramuscular Injection Set (Treatment and Prevention of Symptomatic Disease Caused by SARS-CoV-2 Infection). To investigate intends to evaluate the incidence of adverse drug reactions (ADRs) in individuals who receive Evusheld in clinical practice to determine its post-marketing safety profile in Japanese. The investigation will be conducted as the addtional pharmacovigilance activitiy specified in the Japan Risk Management Plan (J-RMP) of Evusheld in compliance with the Ministerial Ordinance on Good Post-marketing Study Practice (GPSP Ordinance) and for the purpose of application for re-examination under Article 14-4 of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act).
• April 2024:- University of Cologne- A Phase 1/2a Trial of the Intravenous Administration of the SARS-CoV-2-Neutralizing Monoclonal Antibody DZIF-10c in SARS-CoV-2-Infected and -Uninfected Individuals. The phase 1 component of this trial consists of a single intravenous infusion open-label dose-escalation phase (Groups 1A-1D and Group 2C). Subsequently, the highest tested and tolerated dose will be administered to an expansion cohort of SARS-CoV-2-infected individuals (Group 2D). In this randomized and blinded group, participants will receive DZIF-10c or placebo by intravenous infusion.

 

Request a sample and discover the recent advances in COVID-19 @ COVID-19 Pipeline Outlook Report

 

COVID-19 Overview

Coronavirus disease (COVID-19) is an infectious disease caused by the most recently discovered corona virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The disease causes respiratory illness (like the flu) with symptoms such as a cough, fever, and difficulty breathing. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment.

 

COVID-19 Emerging Drugs Profile

• REGN-COV2: Regeneron Pharmaceuticals
• Bucillamine: Revive Therapeutics
• Mupadolimab (CPI-006): Corvus Pharmaceuticals
• VERU‑111: Veru Inc.
• Sarconeos (BIO101): Biophytis
• Leronlimab: CytoDyn
• Tocilizumab: Hoffmann-La Roche

 

Learn more about COVID-19 in clinical trials @ COVID-19 Drugs

 

COVID-19 Therapeutics Assessment

There are approx. 400+ key companies which are developing the therapies for COVID-19. The companies which have their COVID-19 drug candidates in the most advanced stage, i.e. phase III include, Regeneron Pharmaceuticals.

 

DelveInsight’s COVID-19 pipeline report covers around 400+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

 

Discover more about COVID-19 in development @ COVID-19 Clinical Trials

 

COVID-19 Companies

Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., TC BioPharm, Syntax for Science, S.L., Shaperon, Renibus Therapeutics, Quercis Pharma, Pharmenterprises, Pharmamel S.L., Orpheris, OPKO Health, Oncotelic Inc., Notitia Biotechnologies Company, Jazz Pharmaceuticals, Ionis Pharmaceuticals, Inotrem, Grifols Therapeutics LLC, Globavir Biosciences, Genentech, Inc., FSD Pharma, Faron Pharmaceuticals, Evergreen Therapeutics, Enlivex Therapeutics, Eiger BioPharmaceuticals, Direct Biologics, Debiopharm, Clene Nanomedicine, Chiesi Farmaceutici S.p.A., Cadila Healthcare Limited, Biotest, BeiGene, Apeiron Biologics, AgelessRx, AbbVie/Apotex, Telios Pharmaceuticals, Rapa Therapeutics, Organicell Regenerative Medicine, Miltenyi Biomedicine, MedRegen LLC, Kiadis Pharma, Kamada, Cellularity Incorporated, Bio-Thera Solutions, 3M, Sironax, Pfizer, Oncovir, Ology Bioservices, Neutrolis, NeoImmune Tech, Natureceuticals Sdn Bhd, Medicine Invention, Grand Medical, Frontier Biotechnologies, Emergent Biosolutions, Codagenix, Cellenkos, AlloVir, Bausch Health Americas, AiCuris, AgenTus Therapeutics, 4D Pharma, and others.

 

COVID-19 pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Injection
• Intradermal
• Intramuscular
• Intramuscular/intradermal
• Intranasal
• Intranasal/Intramuscular
• Intranasal/Intravenous
• Intraperitoneal
• Intratracheal
• Intravascular
• Intravenous
• Intravenous/subcutaneous
• Oral
• Oral / Enteral
• Oral and Intravenous
• Oral/nasogastric tube
• Parenteral
• Subcutaneous
• Subcutaneous/Intramuscular
• Subcutaneous/Sublingual
• Sublingual
• Topical
• Molecule Type

 

COVID-19 Products have been categorized under various Molecule types such as

• Others
• Peptide
• Protein
• Small Molecule
• Stem Cell Therapy
• Vaccine
• Product Type

 

To know more about COVID-19, visit @ COVID-19 Segmentation

 

Scope of the COVID-19 Pipeline Report

• Coverage- Global
• COVID-19 Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• COVID-19 Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• COVID-19 Companies- Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A., TC BioPharm, Syntax for Science, S.L., Shaperon, Renibus Therapeutics, Quercis Pharma, Pharmenterprises, Pharmamel S.L., Orpheris, OPKO Health, Oncotelic Inc., Notitia Biotechnologies Company, Jazz Pharmaceuticals, Ionis Pharmaceuticals, Inotrem, Grifols Therapeutics LLC, Globavir Biosciences, Genentech, Inc., FSD Pharma, Faron Pharmaceuticals, Evergreen Therapeutics, Enlivex Therapeutics, Eiger BioPharmaceuticals, Direct Biologics, Debiopharm, Clene Nanomedicine, Chiesi Farmaceutici S.p.A., Cadila Healthcare Limited, Biotest, BeiGene, Apeiron Biologics, AgelessRx, AbbVie/Apotex, Telios Pharmaceuticals, Rapa Therapeutics, Organicell Regenerative Medicine, Miltenyi Biomedicine, MedRegen LLC, Kiadis Pharma, Kamada, Cellularity Incorporated, Bio-Thera Solutions, 3M, Sironax, Pfizer, Oncovir, Ology Bioservices, Neutrolis, NeoImmune Tech, Natureceuticals Sdn Bhd, Medicine Invention, Grand Medical, Frontier Biotechnologies, Emergent Biosolutions, Codagenix, Cellenkos, AlloVir, Bausch Health Americas, AiCuris, AgenTus Therapeutics, 4D Pharma, and others.
• COVID-19 Therapies- MAD0004J08, Calcium Dobesilate, Mannitol, IMU-838, Oseltamivir, ILT101, HLX71, and others.

 

For further information on the COVID-19 Pipeline Therapeutics, reach out @ COVID-19 Products Development

 

Table of Content

1. Introduction
2. Executive Summary
3. COVID-19: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. REGN-COV2: Regeneron Pharmaceuticals
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. CNM-ZnAg: Clene Nanomedicine
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. SIR1-365: Sironax
14. Drug profiles in the detailed report…..
15. Preclinical and Discovery Stage Products
16. SB019: Novan
17. Drug profiles in the detailed report…..
18. Inactive Products
19. COVID-19 Key Companies
20. COVID-19 Key Products
21. COVID-19- Unmet Needs
22. COVID-19- Market Drivers and Barriers
23. COVID-19- Future Perspectives and Conclusion
24. COVID-19 Analyst Views
25. COVID-19 Key Companies
26. Appendix

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/